Skip to Main Content
A closer look at Volastra’s lead program: KIF18A inhibitor
September 29, 2022
By Christina Eng, Ph.D., VP, Head of Biology Earlier this month at the FASEB Consequences...
Getting to Know Scott Drutman, M.D., Ph.D., SVP, Head of Translational Science
November 8, 2021
Welcome to Scott Drutman, M.D., Ph.D., who recently joined Volastra as Senior Vice President, Head...
Charting Volastra’s R&D path
October 4, 2021
By Michael Arensman, Aaron Phillips and Hyeseok Shim Every medicine starts with a discovery. But...
Getting to know Rachel Zolot Schwartz, VP, Business Development & Commercial
June 28, 2021
Welcome to Rachel Zolot Schwartz, who recently joined Volastra as Vice President, Business Development &...
June 1, 2021
By Olivier Elemento, Ph.D., Co-Founder Being a student is special. The best students are full...